Table 2. Association between prescription patterns and changes in circulating MBD markers.

Prescription patterns		Improvement in intact PTH			Achievement of target phosphorus			Achievement of target calcium
Cinacalcet	VDRA	Absolute change (pg/ml)	PDa	95% CI	Absolute change (mg/dl)	PDb	95% CI	Absolute change (mg/dl)	PDc	95% CI
Not	Decreased	−67.8	0.01	−0.03 to 0.06	−0.29	0.03	−0.02 to 0.07	−0.14	0.01	−0.03 to 0.05
Not	Stable	−56.7	reference		−0.12	reference	0.13	reference
Not	Increased	−127.6	0.13	0.09 to 0.17	−0.01	0.00	−0.03 to 0.04	0.32	−0.02	−0.06 to 0.01
Starting	Decreased	−141.8	0.19	0.10 to 0.28	−0.82	0.12	0.04 to 0.20	−0.69	0.09	0.01 to 0.17
Starting	Stable	−205.1	0.25	0.19 to 0.31	−0.49	0.03	−0.02 to 0.09	−0.35	0.08	0.02 to 0.14
Starting	Increased	−266.8	0.34	0.25 to 0.42	−0.35	0.07	0.00 to 0.15	−0.16	0.03	−0.05 to 0.11

Abbreviations: CI, confidence interval; MBD, mineral and bone disorder; PD, proportion difference; PTH, parathyroid hormone; VDRA, vitamin D receptor activator.

^aPD for improvement in intact PTH levels (decrease at least one category) adjusting for age, gender, dialysis duration, baseline intact PTH levels, phosphorus levels, calcium levels, use of calcium- or non-calcium-based phosphate binders, single Kt/V, and dialysis calcium.

^bPD for achievement of target phosphorus levels (3.5–6.0 mg/dl) adjusting for potential confounders.

^cPD for achievement of target calcium levels (8.4–10.0 mg/dl) adjusting for potential confounders.

Permission obtained from the American Society of Nephrology.⁷